SCHEMBL7342263

SCHEMBL7342263

CCCCn1nc(C(CCC)(OC)OC)nc1Cc1ccc(-c2cccnc2C(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 3/20 0.46
AGTR2 P50052 2/20 0.46
BRS3 P32247 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7336741 0.97 AGTR1 (0.46) AGTR1AGTR2BRS3
SCHEMBL7340429 0.97 AGTR1 (0.46) AGTR1AGTR2BRS3
SCHEMBL7335001 0.95 AGTR1 (0.43) AGTR1AGTR2BRS3
SCHEMBL7339943 0.94 AGTR1 (0.46) AGTR1AGTR2BRS3
SCHEMBL7332011 0.94 AGTR1 (0.47) AGTR1AGTR2BRS3
SCHEMBL7342981 0.93 AGTR1 (0.46) AGTR1AGTR2BRS3
SCHEMBL7337345 0.92 AGTR1 (0.46) AGTR1AGTR2BRS3
SCHEMBL7335356 0.89 AGTR1 (0.44) AGTR1AGTR2BRS3
SCHEMBL7340689 0.88 AGTR1 (0.47) AGTR1AGTR2BRS3
SCHEMBL9708954 0.88 AGTR1 (0.43) AGTR1AGTR2BRS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6090828-A ARTHERIOSCLEROSIS REITZ DAVID B (US) 2000-07-18 US disclosed
US-5451593-A Method of using 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of a glaucoma disorder G. D. SEARLE & CO. (US) 1995-09-19 US disclosed
US-5451591-A Method of using 5-arylheteroarylalkyl-1,3 5-trisubstituted-1,24-triazole compounds for treatment of circulatory disorders G. D. SEARLE & CO. (US) 1995-09-19 US disclosed
US-5196537-A Angiotensin/II/ antagonists; hypotensive agents G. D. SEARLE & CO. (US) 1993-03-23 US disclosed
EP-0504888-A1 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders G.D. Searle & Co. (US) 1992-09-23 EP disclosed